Vyleesi (Bremelanotide) Monitoring for Adults 30 to 49: Blood Pressure, Side Effects, and Follow-Up Schedule

Why Adults 30 to 49 Need a Specific Monitoring Plan

Women in the 30 to 49 age range represent the core population studied in the RECONNECT Phase 3 trial, where the mean participant age was approximately 39 years [1]. This decade brings overlapping clinical demands: the onset of metabolic risk factors, hormonal fluctuations approaching perimenopause, and common use of hormonal contraceptives that may interact with cardiovascular monitoring thresholds.

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist that the FDA approved in June 2019 specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [2]. The drug's mechanism of action, activating central melanocortin pathways, produces both the desired effect on sexual desire and predictable off-target effects on blood pressure and melanocyte activity [3]. These off-target effects define the monitoring framework.

The Endocrine Society's 2019 guideline on female sexual dysfunction notes that pharmacotherapy for HSDD should include ongoing safety surveillance, particularly in women with cardiovascular risk factors [4]. For a 35-year-old with borderline hypertension or a 42-year-old using combined oral contraceptives, that surveillance takes on practical urgency.

Blood Pressure Monitoring: The First Priority

Transient blood pressure elevation is the most clinically significant safety concern with bremelanotide. In the RECONNECT trial, bremelanotide 1.75 mg produced a mean increase of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 3 hours after injection and returning to baseline within 12 hours [1]. The FDA label lists uncontrolled hypertension and cardiovascular disease as contraindications [2].

Before the first prescription, obtain a seated blood pressure reading. A reading at or above 140/90 mmHg warrants treatment of hypertension before initiating bremelanotide, per ACC/AHA 2017 hypertension guideline staging [5]. Women aged 30 to 49 who use combined estrogen-progestin contraceptives already carry elevated thrombotic and hypertensive risk, and the ACOG Practice Bulletin on hypertension in pregnancy and contraception recommends blood pressure verification before prescribing estrogen-containing methods [6]. The same principle applies here.

A practical monitoring cadence for blood pressure:

• Pre-treatment: Seated clinic blood pressure. If 130 to 139/80 to 89, recheck within 1 week before prescribing.
• Week 2: Patient self-monitors at home 2 to 3 hours post-dose on at least two occasions and reports readings.
• Week 8: In-clinic blood pressure reassessment.
• Every 6 months: Ongoing surveillance, more frequently if the patient develops new risk factors.

Women with readings consistently above 130/80 mmHg post-dose should discuss dose frequency reduction or discontinuation with their provider.

Nausea: The Most Common Reason Patients Stop

Nausea occurred in 40.0% of bremelanotide-treated patients in RECONNECT versus 1.3% on placebo [1]. This was the single most common adverse event and the primary reason for treatment discontinuation in the trial. The FDA prescribing information warns that nausea was severe enough to require an antiemetic in some participants [2].

The nausea is dose-related and appears to diminish with repeated exposure. In the RECONNECT extension study, the proportion of women reporting nausea declined from approximately 40% in the first month to under 25% by month three of continued use [7]. This tachyphylaxis pattern suggests that patients who can tolerate the first 4 to 6 doses often achieve long-term tolerability.

Practical management strategies for the 30 to 49 age group:

• Pre-dose ondansetron 4 mg orally, 30 minutes before injection. A Cochrane review of 5-HT3 antagonists confirms efficacy for drug-induced nausea [8].
• Avoid dosing on an empty stomach. A light meal 1 to 2 hours before injection reduces gastric irritation.
• Evening dosing, which allows sleep to bypass the 2 to 4-hour peak nausea window.
• Dose-spacing strategy: begin with once-weekly use for the first month, titrating to as-needed frequency only after confirming tolerability.

At the 8-week follow-up, ask specifically about nausea severity using a 0 to 10 numeric rating scale. A score persistently above 6 despite antiemetic prophylaxis warrants reconsideration of continued therapy.

Injection-Site Reactions and Self-Administration Technique

Bremelanotide is delivered via a single-dose, prefilled subcutaneous autoinjector to the abdomen or anterior thigh. In the RECONNECT trial, injection-site reactions occurred in approximately 7% of treated patients [1]. Reactions included erythema, bruising, and pruritus, all resolving within 24 to 48 hours.

For women aged 30 to 49 who may have limited experience with self-injection, the initial visit should include a structured training session. The CDC's Safe Injection Practices guidelines outline principles applicable to patient self-injection: proper hand hygiene, site rotation, and single-use device handling [9]. Rotation between the left and right sides of the abdomen and anterior thigh helps reduce cumulative injection-site irritation.

Monitor injection sites at each follow-up visit. Persistent nodules, induration lasting longer than 7 days, or signs of infection (warmth, expanding erythema, purulent discharge) require evaluation. The FDA adverse event reporting system (FAERS) should be used for any serious injection-site reactions [10].

Hyperpigmentation Screening: A Unique Monitoring Need

Because bremelanotide activates MC1R in addition to MC4R, it stimulates melanogenesis. The FDA label reports focal hyperpigmentation (face, gingiva, breasts) in approximately 1% of treated women [2]. In the RECONNECT trial, darkening was typically mild and reversible after discontinuation, but resolution took weeks to months in some cases [1].

Baseline dermatologic documentation is essential. Before initiating therapy, perform or refer for a focused skin exam noting existing pigmented lesions. The American Academy of Dermatology's guidelines on melanoma screening recommend the ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolution) for monitoring pigmented lesions [11]. While bremelanotide-associated hyperpigmentation is benign, any new or changing pigmented lesion in a patient on melanocortin agonist therapy warrants dermatologic evaluation to exclude melanoma.

Women with Fitzpatrick skin types IV, VI may have more baseline pigmented variation, making change detection harder. Standardized clinical photographs of the face and areolae at baseline provide an objective comparator for follow-up assessments. Repeat photography at 6 months and annually provides documentation.

"Patients using bremelanotide should be informed that skin darkening can occur and is generally reversible upon discontinuation," states the FDA-approved Vyleesi Medication Guide [2].

Cardiovascular Risk Assessment in the 30 to 49 Window

The 30 to 49 age range represents a period of emerging cardiovascular risk. NHANES data published in Circulation show that hypertension prevalence among U.S. women aged 35 to 44 is approximately 19%, rising to 31% in the 45 to 54 bracket [12]. Women in this demographic may transition from low-risk to moderate-risk during the course of bremelanotide therapy.

The RECONNECT trial excluded women with uncontrolled hypertension (defined as systolic blood pressure ≥ 140 mmHg or diastolic ≥ 90 mmHg) and those with significant cardiovascular disease [1]. This means the real-world population includes women who were not represented in the key data. The AHA's 2019 primary prevention guideline recommends 10-year atherosclerotic cardiovascular disease (ASCVD) risk calculation for all adults beginning at age 40 [13]. Bremelanotide prescribers should integrate this calculation into their monitoring framework.

For women aged 40 to 49 on bremelanotide, obtain a lipid panel and fasting glucose at baseline and annually. A 10-year ASCVD risk score above 7.5% should prompt reassessment of the risk-benefit ratio of a drug that causes episodic blood pressure elevation. The ACC/AHA pooled cohort equations are available through the ACC ASCVD Risk Estimator [14].

Drug Interactions That Affect Monitoring Intensity

Bremelanotide has no significant CYP450-mediated drug interactions, but its blood pressure effects require attention to concomitant medications. The FDA label notes that bremelanotide slowed gastric emptying in a study with oral naltrexone, reducing naltrexone Cmax by 25% and delaying Tmax [2]. This pharmacokinetic interaction applies broadly to orally administered medications taken around the time of bremelanotide dosing.

Women aged 30 to 49 commonly use medications that compound cardiovascular or pharmacokinetic considerations:

• Combined oral contraceptives: estrogen increases thrombotic risk; adding episodic blood pressure elevation from bremelanotide may compound vascular stress. WHO Medical Eligibility Criteria for contraceptive use classify hypertension as a Category 3 to 4 condition for combined hormonal contraceptives [15].
• SSRIs/SNRIs: antidepressants are a common cause of secondary HSDD and may be the reason for treatment-seeking. A systematic review in the Journal of Clinical Psychiatry reports sexual dysfunction in 40 to 65% of SSRI users [16]. If an SSRI is the underlying cause, switching or dose-reduction may be more appropriate than adding bremelanotide.
• Antihypertensives: women already on blood pressure medication need post-dose monitoring to confirm adequate control persists despite bremelanotide's transient pressor effect.

Counsel patients to take time-sensitive oral medications (thyroid hormone, anticonvulsants) at least 2 hours before or 2 hours after bremelanotide injection to avoid the gastric-emptying delay.

Efficacy Monitoring: When to Reassess Treatment Goals

Bremelanotide is not a medication that produces an easily measurable biomarker change. Efficacy monitoring relies on patient-reported outcomes. The RECONNECT trial used the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) and the Female Sexual Function Index (FSFI) desire domain as co-primary endpoints [1]. Bremelanotide produced a statistically significant improvement in FSDS-DAO score (mean change -0.7 vs. placebo, P<0.001) and FSFI desire domain score.

At the 8-week follow-up, clinicians should:

1. Administer the FSFI desire domain (6 items, takes 3 minutes to complete).
2. Ask about the number of satisfying sexual events in the prior 4 weeks.
3. Assess treatment-associated distress using a simplified numeric rating.
4. Determine actual dosing frequency (patients often use fewer than 8 doses/month).

"The clinical meaningfulness of sexual desire improvement should be assessed from the patient's perspective, not solely from scale scores," according to the ISSWSH Process of Care for HSDD published in Mayo Clinic Proceedings [17].

If a patient reports no meaningful benefit after 8 weeks of consistent use (at least 4 to 6 doses), continuing bremelanotide is unlikely to produce a delayed response. The RECONNECT data showed that treatment separation from placebo was apparent by week 4 [1].

Long-Term Surveillance Beyond the First Year

The RECONNECT open-label extension provided safety data through 60 weeks of intermittent bremelanotide use [7]. No new safety signals emerged beyond those identified in the controlled phase. Blood pressure elevations remained transient and did not accumulate into sustained hypertension. Hyperpigmentation events did not progress to concerning lesions.

For patients continuing bremelanotide beyond 12 months, an annual monitoring visit should include:

• Blood pressure measurement (seated, resting)
• Focused skin examination for new or changed pigmented lesions
• Review of dosing frequency and antiemetic use
• FSFI desire domain score
• Updated cardiovascular risk assessment for women crossing the age-40 threshold
• Review of new medications or diagnoses that might alter the risk-benefit balance

The American College of Obstetricians and Gynecologists recommends annual well-woman visits that already encompass blood pressure screening and preventive counseling [18]. Bremelanotide monitoring integrates naturally into this existing framework rather than requiring separate appointments.

When to Discontinue and How to Document the Decision

Bremelanotide does not cause physiologic dependence, and no withdrawal syndrome has been reported [2]. Discontinuation can be immediate. Stop bremelanotide if any of the following occurs:

• Blood pressure consistently exceeds 140/90 mmHg post-dose despite antihypertensive optimization
• New cardiovascular diagnosis (coronary artery disease, stroke, peripheral arterial disease)
• Persistent severe nausea (NRS ≥ 7) despite antiemetic prophylaxis after 8 weeks
• New focal hyperpigmentation that is cosmetically distressing to the patient
• No subjective efficacy improvement after 8 weeks of adequate use
• Patient becomes pregnant (Category X is not applicable here, but bremelanotide has no pregnancy indication and was not studied in pregnant women per the FDA label) [2]

Document the rationale for discontinuation in the medical record with the specific monitoring parameter that triggered the decision, the date of last dose, and a follow-up plan to confirm resolution of any adverse effects. Hyperpigmentation resolution should be confirmed with follow-up photography 3 to 6 months after the last dose.